The oral clearance and beta-adrenoceptor antagonist activity of propranolol after single dose are not related to debrisoquine oxidation phenotype.
D000319:Adrenergic beta-Antagonists; D003647:Debrisoquin / Q000378:metabolism*; D006801:Humans; D006900:Hydroxylation; D007546:Isoquinolines / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D010084:Oxidation-Reduction; D010641:Phenotype; D011433:Propranolol / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology*
D000319:Adrenergic beta-Antagonists; D007546:Isoquinolines; C001422:4-hydroxypropranolol; D011433:Propranolol; D003647:Debrisoquin